[ biotech news ] Amazon Biotech, Inc. Appoints Dr. Arthur Englard as Scientific Director

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Amazon Biotech, Inc. Announces Appointment of Dr. Arthur Englard as
Scientific Director
NEW YORK, NY -- 09/26/2005 -- Amazon Biotech, Inc. (OTC BB: AMZB)
today announced the appointment of Arthur Englard M.D., Ph.D., as
the Company's Scientific Director.

Dr. Englard is an Assistant Clinical Professor of Medicine at
Columbia College of Physicians and Surgeons and a specialist in
Immunology and HIV medicine. For 20 years, Dr. Englard has been
heavily involved in the AIDS Center Program at St. Lukes/Roosevelt
Hospital Center (New York, NY) ranging from Fellow and Research
Associate to Assistant Director. Additionally, Dr. Englard currently
runs a private practice in New York City. He has extensive
experience working with HIV/AIDS infected patients and with clinical
drug protocol involving AIDS patients.

"I am extremely pleased that Dr. Englard has agreed to be our
Company's Scientific Director," said Dr. Kanovsky, President of
Amazon Biotech. "Dr. Englard's strong life science background will
significantly enhance the knowledge base of our Company. With his
many years of specialized experience in Immunology and HIV medicine,
Dr. Englard has a deep and thorough understanding of the
fundamentals of our approach for treating the disease and the HIV
clinical trial process."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company,
primarily developing immune modulator drugs. AMZ 0026 is the
Company's first such drug, to be used for the treatment of HIV/AIDS.
The Company plans on initiating Phase I/II clinical studies of AMZ
0026 in the near future, with an eventual goal of a attracting a
joint venture partner with a major pharmaceutical company in Phase
III trials, or follow the FDA Fast Track program to market. Amazon
Biotech specializes in natural plant pharmaceutical drugs and is
focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at
www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor'' Statement Under the Private Securities Litigation
Reform Act of 1995 This press release contains forward-looking
information within the meaning of Section 21E of the Securities
Exchange Act of 1934, including statements regarding any potential
sales of products as well as statements that include the
words "believes,'' "expects,'' "anticipates,'' or similar
expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, performance or achievements of Amazon Biotech, to
differ materially from those implied or expressed by such forward-
looking statements. Such factors include, among others, the risk
factors included in Amazon Biotech's subsequent reports filed with
the Securities and Exchange Commission under the Exchange Act. This
press release speaks as of the date first set forth above and Amazon
Biotech assumes no responsibility to update the information included
herein for events occurring after the date hereof.

SOURCE: Amazon Biotech, Inc

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/index.php
http://technorati.com/tag/biotech
http://technorati.com/tag/Biotechnology
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Oncolytics Biotech Inc. Announces Appointment of Chief Medical Officer

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Oncolytics Biotech Inc. Announces Appointment of Chief Medical
Officer

CALGARY, Sept. 27 - Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the
appointment of Karl
Mettinger, MD, PhD, as Chief Medical Officer.
"Dr. Mettinger has been involved with the clinical and regulatory
approval of oncology, cardiovascular, and other products in the
pharmaceutical
industry for twenty years," said Dr. Brad Thompson, President and
CEO of
Oncolytics. "His record includes the implementation of clinical
studies for
more than 25,000 patients worldwide. As part of our senior medical
and
scientific management group which includes Dr. Gill and Dr. Coffey,
Dr.
Mettinger is expected to develop the clinical trial program which
best
supports a registration path for REOLYSIN(R)."
Dr. Mettinger has been involved in clinical and regulatory
affairs with
various pharmaceutical companies since 1985. Prior to joining
Oncolytics, he
was Senior Vice President and Chief Medical Officer with SuperGen
Inc. Prior
to that, he was Executive Director, Clinical Research at IVAX/Baker
Norton,
which is the new drug subsidiary of IVAX Corporation. He began his
career in
the industry with KABI in Sweden. Dr. Mettinger holds an MD from the
University of Lund in Sweden and a PhD (hematology/stroke) from the
Karolinska
Institute in Stockholm, Sweden. He is a member of numerous medical
and
scientific associations including the American Association of
Clinical
Oncology, the American Society of Hematology and the American
Association of
Cancer Research.

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on
the
development of REOLYSIN(R), its proprietary formulation of the human
reovirus,
as a potential cancer therapeutic. Oncolytics' researchers have
demonstrated
that the reovirus is able to selectively kill cancer cells and, in
vitro, kill
human cancer cells that are derived from many types of cancer
including
breast, bladder, prostate, pancreatic and brain tumours, and have
also
demonstrated successful cancer treatment results in a number of
animal models.
Phase I clinical trial results have indicated that REOLYSIN(R) was
well
tolerated and that the reovirus demonstrated activity in tumours
injected with
REOLYSIN(R).

This press release contains forward-looking statements, within
the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended.
Forward-looking statements, including the impact Dr. Mettinger will
have on
the development towards a registration path, the Company's
expectations
related to the advancement of REOLYSIN through the clinical and
regulatory
process, and the Company's belief as to the potential of REOLYSIN(R)
as a
cancer therapeutic, alone, or in combination with other therapies,
involve
known and unknown risks and uncertainties, which could cause the
Company's
actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development
projects, the efficacy of REOLYSIN(R) as a cancer treatment, the
success and
timely completion of clinical studies and trials, the Company's
ability to
successfully commercialize REOLYSIN(R), uncertainties related to the
research
and development of pharmaceuticals, uncertainties related to the
regulatory
process and general changes to the economic environment. Investors
should
consult the Company's quarterly and annual filings with the Canadian
and U.S.
securities commissions for additional information on risks and
uncertainties
relating to the forward looking statements. Investors are cautioned
against
placing undue reliance on forward-looking statements. The Company
does not
undertake to update these forward-looking statements.

SOURCE Oncolytics Biotech Inc.

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/index.php
http://technorati.com/tag/biotech
http://technorati.com/tag/Biotechnology
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] CEA initiates the first French nanobiotech cluster in Grenoble

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

CEA initiates the first French nanobiotech cluster in Grenoble
Grenoble, France | September 27, 2005
CEA (French Atomic Energy Commission) the major European
Technological Research Organisation, announces the creation of the
first French nanobiotechnology cluster. The official launch was made
on September 9th with the signature of a real estate operation
dedicated to host new equipments and research teams in Grenoble
close to the Minatec facilities.

The new cluster, called NanoBio, gathers three research partners:
University Joseph Fourier, Hospital of La Tronche and CEA. A first
phase is going to be funded by local authorities (Metropolitan Area
of Grenoble, Rhone-Alpes Region, Isere Department and City of
Grenoble) for a total amount of 23,5 M€. NanoBio will bring together
engineers, physicists, chemists, biologists and medical doctors to
develop new miniaturised tools for biological and medicine
applications: biochips, lab-on-chips, biosensors… These tools will
be used for medical diagnosis, food safety control, environmental
monitoring, etc.

The aim of NanoBio is to foster the technological and economical
development in the bioengineering field, taking advantage of the
CEA's 10-years experience in biochips and bioMEMS research. NanoBio
is created in synergy with Minatec, the 1st European innovation
Centre for micro and nanotechnology. It will also work in deep
connection with Lyon Biopole, a major biotech cluster dedicated to
diagnosis and vaccines.

Instigator of both Minatec and NanoBio projects, the CEA is
internationally acknowledged for its research in micro and
nanotechnologies for life sciences. LETI (Laboratory of Electronics
and Information Technologies) has dedicated a full department (120
persons) to micro and nanotechnologies for biology and healthcare,
and conducts research projects aimed at technology transfer.

Since 2004, the CEA leads the Nano2Life European network of
excellence, gathering 23 partners in 12 countries and more than 200
scientists. Supported by the European Commission, Nano2Life is
intended to establish the first steps towards an European Institute
of Nanobiotechnology.

####
About CEA Leti:
The CEA plays a major role in research, development and innovation
in three main fields: energy, information and healthcare
technologies, and defence. Set up on 9 centres located all over
France, the CEA benefits from a strong regional insertion and solid
partnerships with other research organisations, local authorities
and universities.

A laboratory of the CEA in Grenoble, the Laboratory of electronics
and information technologies (Leti) is at the leading edge of
European research on microelectronics and micro-nanotechnologies. It
employs more than 900 people. With its 110 patents filed per year
and its twenty-eight start-ups created or in the course of creation,
it is one of the major partners of the industrial world.

For more information, please visit www.cea.fr/gb/index.asp

http://www.arizonabiotech.com/
http://www.arizonabiotech.com/index.php
http://technorati.com/tag/biotech
http://technorati.com/tag/Biotechnology
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Bodisen Biotech, Inc., the First China Based Environmentally Friendly Bio Fertilizer Company Listed on a U.S Stock Exchange to Ring Opening Bell
Bodisen Biotech, Inc., the First China Based Environmentally Friendly Bio Fertilizer Company Listed on a U.S Stock Exchange to Ring Opening Bell at the American Stock

NEW YORK, Sept. 27 Bodisen Biotech, Inc. (Amex: BBC, website: www.bodisen.com) will ring the opening bell at the American Stock Exchange on Thursday, September 29th, in celebration of being the first China based environmentally friendly bio fertilizer company listed on a U.S stock exchange. Bodisen became an AMEX listed company under stock symbol BBC on August 26th.

Bodisen's Chairman & CEO Ms. Qiong Wang, President Bo Chen and other company management members will be present at the ceremony with AMEX officials. The event is coordinated by Wall Street firm New York Global Group and the American Stock Exchange.

Ms. Qiong Wang commented: "Bodisen is very pleased with our listing on the AMEX, which we believe will reflect our status as one of the premier China- based fast growing companies listed in the US. Earlier in 2005, Forbes China ranked Bodisen one of top 100 growth companies in China. For years, Bodisen has provided environmentally friendly bio fertilizer products to a large target market, China's 900 million farmers. Bodisen is focused on its shareholders as well as exemplary corporate governance, and we believe our AMEX listing will positively impact these significant interests."

Ms. Wang stated: "Bodisen's management team is delighted to be in the US and to have the opportunity to meet with our current and prospective institutional shareholders. As we continue to experience strong institutional interest in Bodisen, we look forward to another year of record earnings growth."

About Bodisen Biotech, Inc.

BODISEN TARGETS A LARGE AND GROWING MARKET IN CHINA

Bodisen is a leading manufacturer of environmentally friendly bio fertilizer products serving the needs of China's 900 million farmers. We engage in research, manufacturing and marketing of proprietary technology based agricultural products targeting China's $17 billion per year fertilizer industry.


BODISEN IS A FAST GROWING AND HIGHLY PROFITABLE COMPANY:

Selected Second Quarter 2005 Results Compared to the Same Period in 2004:

* Basic earnings per share of $0.18 (fully diluted: $0.17), an increase of
50% for basic earnings per share and 42% for fully diluted;
* Revenue of $8,416,805, an increase of 99%; Net income of $2,692,014, an
increase of 48%;
* Gross profit of $3,255,664, an increase of 64%

Selected First Half 2005 Results Compared to the Same Period in 2004

* Revenue of $13,118,480, an increase of 104%
* Net income of $3,488,746, an increase of 55%
* Gross profit increased 72% compared to the six month period ended June
30, 2004
* Basic earnings per share of $0.23 (fully diluted: $0.22), an increase of
53% for basic earnings per share and 47% for fully diluted

BODISEN FACES FAVORABLE MARKET ENVIRONMENT IN CHINA
We are a unique company in a favorable market environment. China exports many things to the world marketplace; however is one of the largest importers of grains and foods in the world. Hundreds of millions of Chinese depend on imported grains to support higher demand for meat and poultry which are fed with imported grains. The Chinese government has mandated that farmers increase crop yields to decrease the nation's dependence on foreign imports. Moreover, there is growing emphasis on the need for "green" fertilizers that restore the soil, rather than deplete it.

BODISEN HAS A FULL LINE OF PRODUCTS THAT EFFECTIVELY ADDRESS COMPLETE PLANTING NEEDS OF CHINESE FARMERS

With over 60 products and approximately 600 national distribution centers and growing, Bodisen has experienced rapid growth in recent years. Bodisen's products are developed by company scientists in collaboration with University laboratories. Our products address grains, vegetables, fruit crops and have been proven to increase yields by 10% to 35% while 100% environmentally friendly. Our products substantially improve the lifestyles of the 900 million Chinese farmers whose livelihood are solely dependent upon their crop yields.

EARNINGS GUIDANCE FOR YEAR 2005

Bodisen affirmed fiscal 2005 (December yearend) guidance for earnings of approximately $8 million (including 1Q05 one time financing related charge), or approximately 50 cents per share, on revenue of approximately $28 million. Guidance does not include positive impact from increased sales channels and further expansion of manufacturing capacities, as a result of the Company's planned dual listing before yearend on the AIM market of the London Stock Exchange raising up to 10 million British Pound (US$18 million) through placement of new shares (Broker: UK investment bank Charles Stanley; Reporting accountant: Deloitte & Touche).

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.




--------------------------------------------------------------------------------
Source: Bodisen Biotech, Inc.


Weblogs Blogs Blogging biotech Biotechnology


BIOTECH NEWS
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Corgentech to merge with AlgoRx
Corgentech to merge with AlgoRx


Drug developer Corgentech Inc. announced it agreed to merge with AlgoRx Pharmaceuticals Inc. to create a company with late-stage products.


Weblogs Blogs Blogging biotech Biotechnology


BIOTECH
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News - Serologicals - Biotech company announces closure
Newsday.com: Biotech company announces closure

Biotech company announces closure

September 26, 2005, 9:57 PM EDT


LAKE PLACID, N.Y. -- Biotechnology firm Upstate on Monday morning told its 60 employees that it will shut down operations this spring.

The move follows an earlier round of job cuts in which another 60 people were laid off or offered the chance to relocate to California, where Upstate's parent company, Serologicals Corp., has another facility.

Serologicals, based in Atlanta, bought the company in September 2004.

Weblogs Blogs Blogging biotech Biotechnology


BIOTECH
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotechnology conference to highlight Charlotte�s emerging role Monday - Science/Technology - News
Lincoln Tribune - Biotechnology conference to highlight Charlotte�s emerging role Monday - Science/Technology - News

Biotechnology conference to highlight Charlotte’s emerging role Monday
Posted by Anonymous on 2005/9/21 19:10:00 (25 reads) News by the same author
A discussion on the rapidly expanding biotechnology infrastructure in Charlotte, cutting-edge research projects, market insight and biotech investments will be highlighted at the fourth annual UNC Charlotte Biotechnology Conference.

The event will take place Monday Sept. 26, at UNC Charlotte in the Barnhardt Student Activity Center, third floor salons. The event is open to the public and begins with a networking breakfast at 7:30 a.m.



Biotech News 1 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Overcoming Adoption Challenges for Pharma Industry Highlighted at Patient-Level

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Overcoming Adoption Challenges for Pharma Industry Highlighted at
Patient-Level Data Conference, November 2-3, Arlington, VA


ARLINGTON, Va., Sept. 15 Strategic Research Institute is
pleased to announce the upcoming Patient Level Data for the
Pharmaceutical Industries conference scheduled to take place on
November 2-3, 2005 in Arlington, VA. This conference will focus on
how patient-level data boosts pharma marketers strategic decision
making and marketing effectiveness, whether they are marketing to
managed markets, physicians, consumers, or policy-makers.

As patient-level data continues to be adopted by marketers, a
new level of precision is compelled to pharmaceutical sales and
marketing strategies. By providing an evidence-based assessment of
physician treatment practices and patient outcomes, pharmaceutical
companies get a better understanding of untapped market potential.
This information leads to better decisions regarding resource
allocation, targeting, positioning, and messaging.

The conference features presenters from industry such as big
pharmaceutical manufacturers and service providers of marketing
information.
Complete list of presenters includes: Amgen, Inc., Access Biotech,
AstraZeneca, Bayser, Biotechnology Association, Bloom Marketing
Solutions,
Booz Allen Hamilton, Bristol-Myers Squibb, Centocor, Inc.,
Commodicast, Inc.,
IMS Health, NDC Health, Pfizer, Inc. Pharmetrics - A Unit of IMS
Health,
Sanofi Aventis, Solvay Pharmaceuticals, Inc., V2Gfk & University of
Utah
College of Pharmacy.
The keynote to be featured on the first day morning plenary
is "Patient
Level Data - Overcoming Adoption Challenges," presented by Joyjit
Saha
Choudhury & Charley Beever of Booz Allen Hamilton, followed by the
keynote
entitled, "Using Longitudinal Data for Knowledge-Based Decision
Making,"
presented by Mark Stevens of Sanofi Aventis.
Interactive panels featured on the agenda are: 1) Leveraging
Patient Level
Data to Develop Physician Referral Patterns, Methodologies and
Business
Implications -- moderated by Solvay Pharmaceuticals, and 2) Patient
Level Data
Revolutionizing Marketing Effectiveness, an Interactive Discussion --
moderated by Booz Allen Hamilton.
To register for the conference, please visit
www.srinstitute.com/cs329.
THE LAST DAY TO REGISTER AT THE DISCOUNTED RATE ($400 OFF) IS
FRIDAY, SEPT.
16TH.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php
http://www.mail-archive.com/biotech-news@yahoogroups.com/
http://www.mail-archive.com/biotech-
news@yahoogroups.com/maillist.html

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Spectrum Pharmaceuticals Enters Into Definitive Agreements to Raise $42 Million

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Spectrum Pharmaceuticals Enters Into Definitive Agreements to Raise
$42 Million in Public Offering With Leading Biotech Institutional
Investors

Spectrum Pharmaceuticals, Inc. today announced that it has entered
into definitive agreements to raise approximately $42 million
through the issuance of approximately 8 million shares of its common
stock at a price of $5.25 per share. In addition, purchasers of the
common stock will receive six-year warrants to purchase up to
approximately 4 million shares of the Company's common stock at an
exercise price of $6.62 per share. The shares of common stock and
warrants will be issued pursuant to an effective shelf registration
statement.

http://www.arizonabiotech.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

Rodman and Renshaw, LLC acted as the exclusive placement agent for
the offering. The net proceeds from the offering realized by the
Company will be used for general corporate purposes. A copy of the
final prospectus relating to the offering may be obtained from Shyam
Kumaria, Vice President Finance, Spectrum Pharmaceuticals, Inc., 157
Technology Drive, Irvine, CA 92618-2402.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/

Spectrum Pharmaceuticals is a specialty pharmaceutical company
engaged in the business of acquiring, developing and commercializing
prescription drug products for the treatment of cancer and other
unmet medical needs.

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech Center
Local10.com - News - Land Swap Will Create New Homeless Shelter, Huge Biotech Center

Land Swap Will Create New Homeless Shelter, Huge Biotech Center

POSTED: 6:03 pm EDT September 14, 2005

MIAMI -- A land-swap deal announced Wednesday is expected to provide both a new home for the homeless and a biotech center that will provide thousands of jobs.

For more than 20 years, Camillus House has offered the homeless a place to stay. For years, developers have said that even though the building has served an important purpose, it has also held up development in the area.

Wednesday, city and University of Miami officials announced that Camillus House will swap property it owns near the UM medical school complex for land the university needs for a huge biotech science center.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech Stocks: Biopharma indexes diverge, Dendreon soars - Biotechnology - Pharmaceuticals - Stock Reports - Market News
Biotech Stocks: Biopharma indexes diverge, Dendreon soars - Biotechnology - Pharmaceuticals - Stock Reports - Market News

BIOTECH STOCKS

Biopharma indexes diverge, Dendreon soars

By Val Brickates Kennedy, MarketWatch

BOSTON (MarketWatch)-The benchmark sector indexes diverged on Wednesday while shares of Dendreon staged a late-day rally on positive news for its drug Provenge.

The Amex Biotechnology Index

Dendreon (DNDN: news, chart, profile) shot up 13%

Celgene (CELG: news, chart, profile) shares rose 4% to $54.77, after being halted

An advisory panel of the Food and Drug Administration voted midday to recommend Revlimid be approved to treat a type of anemia caused by myelodysplastic syndromes, a group of diseases that cripple the body's ability to make healthy blood cells.

Progenics Pharmaceuticals

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Novavax Announces Strategic Alliance on Pandemic Influenza Vaccine Production Te

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Novavax Announces Strategic Alliance on Pandemic Influenza Vaccine
Production Technologies

MALVERN, Pa., Sept. 13 -- Novavax, Inc.
(Nasdaq: NVAX) and Wave Biotech, LLC located in Somerset, NJ, today
jointly
announced that they will collaborate on the development of a
commercial scale
production process for Novavax's pandemic influenza virus (avian
flu) vaccine
and other biological products. Initially, the companies will focus
on
Novavax's H9N2 avian flu Virus-Like Particle (VLP) vaccine that has
shown
promising results in preclinical studies.
Wave Biotech will provide process and equipment expertise for the
proprietary technology based on disposable equipment for the
manufacture of
biologicals. Novavax scientists will work with the engineering team
at Wave
Biotech to further develop the process for the manufacture of
vaccines and
other biological products.
"We are very pleased to be able to work with Wave Biotech as we
proceed to
expand the production of our pandemic and seasonal flu vaccine
candidates. The
process is reliable and can be readily scaled up to meet the needs
of large
populations," said Dr. Rahul Singhvi, President and CEO of
Novavax. "We have
experienced excellent results to-date with Wave Biotech's equipment
in the
production of influenza as well as HIV/AIDS, SARS, and other VLP
vaccines for
human diseases. A manufacturing strategy based on Wave Biotech's
technology
combined with our recombinant DNA based approach to vaccine
production should
enable us to rapidly respond to demand. In addition, this new
technology
allows us to go into commercial scale manufacturing with lower
capital
investment than with traditional production methods for vaccines."
"Wave Biotech's disposable cell culture technology is ideal for
the
Novavax application," commented Dr. Vijay Singh, President of Wave
Biotech.
"It provides scalable technology that can be delivered, installed and
commissioned quickly for possible worldwide use."

About Virus-Like Particle (VLP) Technology
Novavax's VLP vaccine approach uses recombinant DNA technology
to create
components of the influenza virus in structures optimized to elicit a
protective immune response. The three dimensional virus like
structures are
designed to give protection without the risk of infection and
without the
addition of chemical adjuvants. Novavax's proprietary process
produces
vaccines aseptically, reduces contamination risk and leads to high,
cost-effective yields.

About Wave Biotech's Disposable Manufacturing Technology
Wave Biotech is a research-based company that develops and
manufactures
innovative process equipment for the pharmaceutical and biotechnology
industry. The Company's focus is on developing disposable bioprocess
equipment
for operations traditionally requiring stainless-steel tanks and
piping. Key
products, such as the Wave Bioreactor(R), Wave Mixer(R), FlexMixer
(TM) and
Sterile Tube Fuser, feature disposable contact materials that
eliminate
cleaning and validation, thereby reducing costs in operations
ranging from
cell culture, media preparation, buffer dissolution and thawing
process
intermediates to patient-specific cell therapy in hospitals. These
unique,
patented, devices can be installed and commissioned rapidly,
drastically
reducing the time-to-market for biological products. Wave Biotech's
equipment
is in use with hundreds of companies worldwide, both for R&D, as
well as
commercial applications.

About Novavax, Inc.
Novavax, Inc. is a specialty biopharmaceutical company focused
on the
research, development and commercialization of products utilizing its
proprietary drug delivery and biological technologies for large and
growing
markets. Novavax currently distributes a line of prescription
pharmaceutical
products, including its topical emulsion for estrogen therapy
ESTRASORB, and
prenatal vitamins.

Statements made in this press release that state Novavax's or
management's
intentions, hopes, beliefs, expectations, or predictions of the
future are
forward-looking statements. Forward-looking statements include but
are not
limited to statements regarding usage of cash, product sales, future
product
development and related clinical trials and future research and
development,
including FDA approval. Novavax's actual results could differ
materially from
those expressed in such forward-looking statements. Such forward-
looking
statements involve known and unknown risks, uncertainties and other
factors
which may cause the actual results, performance or achievements of
the
Company, or industry results, to be materially different from those
expressed
or implied by such forward-looking statements. Such factors
include, among
other things, the following: general economic and business
conditions; ability
to enter into future collaborations with industry partners,
including an
ESTRASORB(R) licensing agreement; competition; unexpected changes in
technologies and technological advances; ability to obtain rights to
technology; ability to obtain and enforce patents; ability to
commercialize
and manufacture products; ability to establish and maintain
commercial-scale
manufacturing capabilities; results of clinical studies; progress of
research
and development activities; business abilities and judgment of
personnel;
availability of qualified personnel; changes in, or failure to
comply with,
governmental regulations; the ability to obtain adequate financing
in the
future through product licensing, co-promotional arrangements,
public or
private equity financing or otherwise; and other factors referenced
herein.
Additional information is contained in Novavax's annual report on
Form 10K for
the year ended December 31, 2004 and quarterly reports on Form 10Q
for the
quarters ended March 31, 2005 and June 30, 2005, incorporated herein
by
reference. Statements made herein should be read in conjunction with
Novavax's
annual and quarterly reports filed with the SEC. Copies of these
filings may
be obtained by contacting Novavax at 508 Lapp Road, Malvern, PA 19355
Tel 484-913-1200 or the SEC at http://www.sec.gov.

SOURCE Novavax, Inc.

http://www.azhttp.com/seo.htm
http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Missouri Governor Matt Blunt Honored With Significant National Biotech Award
Gov. Matt Blunt Honored With Significant National Biotech Award


ST. LOUIS, Sept. 13 -- Gov. Matt Blunt today received the
national Biotechnology Industry Organization (BIO) "Award for
Leadership Excellence" for his support of the biotechnology and life science
industries in Missouri.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums

Blunt received the award from state and national biotechnology
leaders at
the Donald Danforth Plant Science Center. The ceremony was held in
conjunction with the inaugural meeting of the Advisory Council for
Plant
Biotechnology. The council is charged with assessing the state's
current
plant bioscience environment to determine how the state can best
capitalize on
its assets and emerge more fully as a world-class life sciences
leader.
"Governor Blunt has demonstrated significant leadership by
directing the
state's focus on a number of life science issues," said Kelly
Gillespie,
executive director of the Missouri Biotechnology Association
(MOBIO). MOBIO
is a statewide nonprofit trade association dedicated to development
and growth
of the Missouri biotechnology and biomedical industry and is the
recognized
state affiliate of BIO. "This award from the national organization
is
recognition of the great bioscience achievements being developed in
Missouri,
as well as recognition that this governor has committed to
protecting,
nurturing and encouraging this important economic sector which is
known for
creating high-quality, stable jobs."
"Governor Blunt understands the need to protect Missouri's
national
reputation as a science-friendly environment. Blunt's key leadership
appointments to the departments of agriculture and economic
development have
been applauded by industry observers. Missouri farmers are poised
to leverage
their production abilities with greater stewardship toward the
environment
than ever before. The advisory council is yet further evidence of
the
governor's vision to encourage ethical, sound-science based policy
directives," said Gillespie.
The Missouri Biotechnology Association (MOBIO) is a nonprofit
trade
association that serves all Missouri organizations interested in the
life
sciences. MOBIO is composed of a broad cross-section of companies,
institutions of higher education, research organizations and related
firms
involved in research, development and commercialization of the life
sciences,
plant sciences and animal sciences. MOBIO members promote economic
development in Missouri by supporting life science research and
practical
applications that benefit the general population.

MOBIO is the state affiliate of the Biotechnology Industry Organization (BIO).SOURCE Biotechnology Industry Organization

Web Site: www.bio.org

Biotech
Biotech
Recipes
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Key to stem cell transplant success is tricking immune system

Key to stem cell transplant success is tricking immune system

Friday 9 September 2005

Tricking the bodys immune system into ignoring stem cells will be
the key to successful stem cell transplants, according to Professor
Maggie Dallman , Imperial College London, speaking today at the BA
Festival of Science.

Professor Dallman is investigating how to trick the body into
producing regulatory cells, which prevent the bodys immune system
from attacking its own molecules, at the site of a stem cell
transplant. If they were present when stem cells were introduced
into the body, the regulatory cells would inhibit the bodys natural
response to 'foreign' cells, meaning the stem cells would be
accepted.

Drug therapies can prevent traditional organ grafts from being
destroyed in the short term but organ transplants typically fail
after a number of years as the bodys immune system rejects the new
tissue. Scientists are hopeful that harnessing regulatory cells
would prevent stem cell transplants from facing similar rejection.

Professor Dallman, from Imperials department of Cell and Molecular
Biology, explains: "Stem cell transplants will offer fantastic
possibilities for helping people with any disease where there is
tissue damage or degeneration. It is vital to work out how to
prevent these transplants from being rejected.

"We know from over 50 years of experience with transplants that a
major issue affecting the success of such procedures is the immune
systems rejection of grafted tissue. Our recent experiments suggest
that we could use regulatory cells to stop the immune system
responding to foreign transplants, whilst leaving the rest of the
immune system intact", she adds.

Cloning stem cells using a patient's own cells is another option for
preventing the rejection of stem cell transplants. This would have a
low risk of rejection because cloned cells would contain the
patients own DNA. However, the cost and intricate nature of this
procedure means that it may not prove to be a practical option for
widespread use, according to Professor Dallman.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Medipacs, L.L.C. teams up with Tucson Embedded Systems,
Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Medipacs, L.L.C. teams up with Tucson Embedded Systems,
for safety critical software.

Medipacs announced today it has formed a development and equity
partnership with Tucson Embedded Systems for undisclosed terms.

Medipacs a Tucson biotech company is developing advanced infusion
technology based on it's new digital pump system. Tucson Embedded
System is a Tucson based engineering firm that develops safety
critical software.

Medipacs recently unveiled the first Digital PumpTM and is now
focusing on it's first commercial application, a programmable
disposable infusion pump. The Medipacs proprietary pump technology
known as pulse activated cell systems, (PACS) uses electrically
activated polymers in a computer controlled environment that
eliminates the need for electric motors and pump mechanisms.

The Medipacs application is for a market of over ONE MILLION
INFUSIONS that happen every day in the United States.

Tucson Embedded Systems Inc (TES) is ISO 9001:2000 engineering firm.
TES
specializes in safe and robust embedded systems for control and
communications applications for the aerospace, transportation,
military, scientific, and medical communities.

Tucson Embedded Systems VP of Business Services Dennis Kenman, is
excited about the relationship with Medipacs. "The Medipacs
technology for a programmable disposable infusion pump has never
been done before. We are committed to building the embedded systems
and programming software that will deliver a safer and more
affordable pump. This equates directly to increased patient safety
and lower patient cost."

Medipacs systems engineer, Sonia Vohnout, sees huge possibilities
with TES as a partner. "With TES as an equity partner, they will
lower our engineering and development costs and with a staff of over
50 engineers working on the Medipacs control & software design, they
will help accelerate us into the marketplace ."

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies

Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies



Leading biotech companies like Pfizer are increasingly interested in acquisition of smaller biotech companies whose products are in the early phase 2 clinical trials. “Smaller companies are more willing to consider acquisition then they used to be,” notes Roger Longman, Managing Partner at Healthcare business information specialist for Windhover information. The possibilities of going public after acquisition is very high for these small companies and is one of these reasons these companies are considering a big pharma buy out.

This year lot of companies have choose acquisition – San Diego based Idun Pharmaceutical and Syrix Pharmaceuticals (Pfizer), TransForm Pharmaceuticals and NeoGenesis, both located outside Botson (Johnson & Johnson and Scherring-Plough).

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
State catching up in the biotech race
State catching up in the biotech race

State catching up in the biotech race

Max Jarman
The Arizona Republic
Sept. 11, 2005 12:00 AM

Arizona's emerging biotech industry is growing slowly but making clear progress.

And while the state still lags significantly behind mature biotech hot spots such as San Diego and Boston, it is catching up faster than many people expected.

"This is a marathon, not a sprint," said Walter Plosila, a vice president with Battelle, a non-profit research firm hired to chart the state's biotech progress. advertisement




An interim progress report prepared by Battelle found that from 2000 to 2004, the state recorded solid growth in the number of bioscience companies, related jobs and average wages.

Arizona also made important strides in research funding, venture-capital investment and new product development.

As if to emphasize the point, InNexus Biotechnology Inc., a Canadian-based company, announced last week that it would locate its U.S. headquarters and a research facility in Scottsdale's Mayo Clinic.

"We're seeing interest because these companies see things happening here," said Jon McGarity, chairman of the Arizona BioIndustry Association. McGarity said he is working with five other bioscience companies interested in locating in Arizona.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] BIO InvestorForum 2005 Spotlights Biotech Companies Poised for Growth

BIO InvestorForum 2005 Spotlights Biotech Companies Poised for Growth

Media Registration Now Open for Oct. 18-20 San Francisco Conference

WASHINGTON, Sept. 8 Media registration is now open for BIO
InvestorForum 2005, Oct. 18-20 in San Francisco at The Palace Hotel.
Organized by the Biotechnology Industry Organization (BIO), BIO
InvestorForum 2005 will focus on the biotechnology companies,
clinical development areas and research programs that are considered
to be investor growth areas.

"This conference is the best opportunity this fall for biotechnology
journalists to meet industry leaders, including CEOs, clinical
investigators and financial experts, and discover the trends that
will shape the biotechnology industry in the coming year," said
Morrie Ruffin, BIO's Executive Vice President, Capital Formation
Section and Business Development.

The BIO InvestorForum 2005 will feature select company
presentations, dynamic panel discussions and keynote speeches on
such topics as clinical strategy, product development and the
shifting regulatory landscape. Discussion will center on growth
potential for both public and private companies, as well as the
areas most likely to be considered for the "growth watch list" in
2006. In attendance will be institutional investors, venture and
private equity investors, as well as research analysts and bankers
representing leading banks in the sector.

A series of Therapeutic Workshops and CEO Roundtables will explore
hot topics and debate the growth challenges facing the industry.
Therapeutic topics include:

- Developing New Pain Therapeutics in the Post-Vioxx World
- Clinical Development and Regulatory Trends in the Era of
Targeted
Cancer Therapies
- Cancer Genome Sequencing Project, Part 1: Implications for
Sequencing
Technology
- Sleeping Giant: Opportunities in Sleep Disorders
- New Strategies and New Hope in Lupus
- Cardiovascular Disease: Not for the Faint-Hearted

The slate of CEO Roundtable sessions was developed based on popular
demand and includes:

- Tales from the Trenches: Getting Through an IPO and Thriving
in the
Aftermarket
- Demystifying Hedge Funds
- Increasing Valuation Through Milestone-Driven Development
Strategy and

Strategic Outsourcing
- New Fundraising Strategies and Case Studies in the Current
Public
Financing Environment
- The Last Word on the Watch List for 2006: The Buyside Versus
Investigator View of Events that Will Shape 2006

Full conference details and online registration are available at
http://www.bio.org/. The hosts of the BIO InvestorForum 2005 are
Bank of America and Lehman Brothers. Co-hosts are CIBC World
Markets, Jefferies, and RBC Capital Markets. Supporting Partners are
BayBio, BIOCOM and BIOTECanada.

About BIO

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and in 31 other nations. BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.

Source: Biotechnology Industry Organization

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Environmental Journalism Conference Is Packed With Katrina-Related Content
Environmental Journalism Conference Is Packed With Katrina-Related Content

JENKINTOWN, Pa., Sept. 8 "Everyone is an environmental journalist now," says SEJ Executive Director Beth Parke.


This is one of those rare moments when a slow-motion environmental disaster becomes a fast-breaking news event.


Is your newsroom prepared?


You can get up to speed fast at the Society of Environmental Journalists' annual conference hosted by The University of Texas at Austin, September 28th - October 2nd.


IT'S NOT TOO LATE TO REGISTER for the premiere event on environment and media this year. Visit http://www.sej.org/confer/index1.htm for full conference details.


SEJ's annual conference is a rich mix of field trips, keynote speeches, plenary sessions, panels, and how-to craft sessions -- everything from taking your own water samples to filing a Freedom of Information request.


HIGHLIGHTS:


SPEAKERS: Molly Ivins, author and columnist, Fort Worth Star-Telegram; Bill Moyers, broadcast journalist and president, Schumann Center for Media and Democracy.


ROUNDTABLE ON COVERING OIL & ENERGY: Lynn Laverty Elsenhans, Shell; Rich Marcogliese, Valero; Sherri Stuewer, Exxon Mobil; and Matthew Simmons, author of "Twilight in the Desert: The Coming Saudi Oil Shock and the World Economy"


FIELD TRIPS: Texas energy tour, Houston ship channel tour, Austin flood alley and riverboat trip, East Austin tour of race and environmental impacts on health.


COVERING DISASTERS: hurricanes, tornadoes, earthquakes, wildfires, volcanoes, oil spills, chemical and nuclear releases and explosions, and shuttle disasters.


GULF COAST SPRAWL, TSUNAMIS, HURRICANES AND COASTAL DEVELOPMENT: with Mark Schleifstein, Environment Reporter for The (New Orleans) Times-Picayune


BUSH ENVIRONMENTAL RECORD: with Juliet Eilperin, The Washington Post; Congressman Richard Pombo, Chairman, U.S. House Resources Committee; William O'Keefe, George Marshall Institute; Pat Parenteau, Vermont Law School; and Carl Pope, Sierra Club


ENVIRONMENTAL ISSUES IN THE AMERICAS: Freedom of Information and Nuclear Waste in Mexico; Big Business and the Rainforest; Ecotourism; Species and Cross Border Migration; Biotech Crops; NAFTA. Presentations in Spanish and English.


PLENARY ON THE FUTURE OF JOURNALISM: Judy Muller, ABC News and Annenberg School for Communication, University of Southern California; Rick Rodriguez, The Sacramento Bee, President, American Society of Newspaper Editors; Merrill Brown, News for the 21st Century and Carnegie-Knight Initiative on the Future of Journalism Education; Bebe Crouse, National Public Radio; Nick Gillespie, Reason Magazine; Jay Harris, University of Southern California; Andrew Revkin, The New York Times


AUTHORS of new and forthcoming books, including former Secretary of the Interior Bruce Babbitt, Rocky Barker, David Helvarg, Dick Russell and others.


PANEL SESSIONS: Oil, Plant and Pipeline Safety; Gulf Coast Rivers, Bays and Estuaries; Gulf Coast Dead Zones; Enforcing Environmental Laws; Sprawl; Desalinating the Gulf of Mexico; Green Energy Alternatives; Science and the Media


WORKSHOPS: How to File a Freedom of Information Act Request; Internet Investigations; Money in Politics Computer Lab; Using Online Databases, Blogs, Feeds, Wikis, and Podcasts.


DO-IT-YOURSELF TESTING: Reporters Conduct Their Own Environmental Sampling: Sara Shipley Hiles; Chris Bowman, The Sacramento Bee; Ben Raines, Mobile Register


SPECIAL EVENTS: Ride and Drive Advanced Technology Vehicles; SEJ Awards for Reporting on Environment; Reception and Party at the Bob Bullock Texas History Museum; Exhibits.


The Society of Environmental Journalists (SEJ) is the world's oldest and largest membership organization of individual working journalists who cover environment-related issues. SEJ's membership of more than 1,450 includes reporters, producers and editors in print, broadcast and online news media in the United States, Mexico, Canada and 31 other countries.


For complete conference details and to register online, visit SEJ on the Web at http://www.sej.org/confer/index1.htm .


Society of Environmental Journalists
PO Box 2492, Jenkintown, PA 19046
ph (215) 884-8174 fx (215) 884-8175

http://www.sej.org/


Dedicated to improving the quality, accuracy and visibility of environmental reporting.


Source: Society of Environmental Journalists






Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News




Famous Quotes Love Quotes 9/11 Quotes domain name Life Quotes CrockPot Recipes Marketing Firms Scottsdale Dentist Casserole Recipes Love Quotes Salmon Recipes Love Poems Website Marketing Recipes Funny Quotes Funny Quotes Love Quotes Famous Cooking Recipes Funny Quotes Fireplace Mantels flowmeters Dental Coupons Famous Quotes Sugar Free Recipes Vegetable Gardening Dental Office Free Recipes Garage Storage Cabinets Diabetic Recipes
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Winston-Salem Journal | Billionaire to unveil plan for biotech center at old textile site
Winston-Salem Journal | Billionaire to unveil plan for biotech center at old textile site

Billionaire to unveil plan for biotech center at old textile site


By PAUL NOWELL
AP Business Writer

CHARLOTTE, N.C. - Two years after nearby Kannapolis was the epicenter of the largest mass layoff in North Carolina history, hope may rise from the rubble of a massive demolished plant.

California billionaire David Murdock will come to town Monday to unveil plans for a biotechnology complex on the former site of Pillowtex Corp. Plant 1, which dominated downtown Kannapolis for decades as the employer of thousands. Then came the slowdown of the state's textile industry. And in July 2003, the plant was shuttered as the company shut down and shed 4,800 jobs.
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News - A World Without Hunger
Truth About Trade & Technology - A World Without Hunger

A World Without Hunger

by: Rakesh Mehar


Despite the major technological growth in the last few decades, food security still remains one of the major problems faced by the developing world. According to experts, a total of 800 million people, or one in every six people in the developing world do not have access to food. India, with the world’s second highest population, lists nearly 200 million under the poverty line, with poor access to food. Moreover, the agricultural sector in the nation supports two thirds of the nation’s population, but generates only one fourth of the national income.

Agricultural scientists say one of the primary concerns for Indian agriculture is that while population grows at a meteoric rate, there is a lack of availability of arable land. Although India has over 16 per cent of the world’s population, it possesses only two per cent of arable land. Moreover, problems such as desertification continually contribute to a further decline in available land. The steadily decreasing size of agricultural holdings of small farmers has also hit productivity hard. With the rapid rise in population and lack of means to increase net area of arable lands, increasing yield and productivity is the only means of ensuring proper food supply. However, traditional methods of breeding high yielding crops are inefficient in the present context, says Dr M N Sheelavantar, Vice Chancellor, University of Agricultural Sciences, Bangalore.

The chief difficulty arises from the non-availability of suitable species of plants for traditional breeding. He adds "In the last 50 years, we have exploited all the available plant species and natural breeding methods, and raised productivity levels by ten times. However, we can’t go any further because the hybrid vigour is on the decline, and no more desirable variations are available for plants to be crossed with." GM crops on the other hand, allow scientists to extract the DNA of any organism, animal or plant and insert it into target crops. Thus GM crops allow for the use of a much larger gene base than traditional crops. The second problem, he says, arises from the significantly longer time period required to create viable hybrid products using traditional methods. Traditional breeding requires a cycle of seven to 10 years to produce a usable product, time we do not have. On the other hand, a normal GM cycle would only take around three years.
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Winning Legal Strategies for Biotech Companies: Intellectual Property Protection, FDA Approval, and Board Management for the Biotech Industry
Winning Legal Strategies for Biotech Companies: Intellectual Property Protection, FDA Approval, and Board Management for the Biotech Industry

DUBLIN, Ireland Sept. 5, 2005--Research and Markets (http://www.researchandmarkets.com/reports/c23707) has announced the addition of Winning Legal Strategies for Biotech Companies: Intellectual Property Protection, FDA Approval, and Board Management for the Biotech Industry to their offering.


Winning Legal Strategies for Biotech Companies is an authoritative, insider's perspective on the issues surrounding biotechnology law including patent protection, assessment of intellectual property, and the future of biotech law, on a global scale. Featuring department heads, group chairs, and leading partners, all representing some of the nation's top firms, this book provides a broad yet comprehensive overview of the practice of biotech law discussing the current shape and future state of guidelines for FDA approval from the founding doctrines to the pivotal cases of today.

From the steps involved in developing legal strategies to crucial tactics around counseling clients in a competitive market, these authors articulate the finer points around biotechnology now, and what will hold true into the future. The different niches represented and the breadth of perspectives presented enable readers to get inside some of the great legal minds of today as experts offer up their thoughts around the keys to success within this fascinating practice area.

Topics covered:

-- Legal Strategies for Biotechnology Companies

-- Successful Biotechnology Companies: Developing the Legal Strategy

-- Counseling Biotech Companies in a Competitive Market: The Interplay between Freedom to Operate and Patent Protection

-- Practical Advice for the Biotech Entrepreneur

-- The Key Asset: How to Build a Great Board and Effective Board-Management Communication

-- Guidelines to Follow for FDA Approval

-- Continuous Capture and Assessment of Intellectual Property





Quotes Recipes Funny Quotes Arizona Search Engine Optimization Associations and Memberships Small Business Partners
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Workshop to Focus on NanoBiomaterials Derived from Lignocellulosics

Workshop to Focus on NanoBiomaterials Derived from Lignocellulosics
Thursday September 1, 6:59 pm ET

ATLANTA, Sept. 1 -- This nation's forest resources play an important
role in the economic, social, and environmental performance of the
U.S. and represent one of the top five global forest reserves.
Recent changes in national and international competitiveness of the
forest products industry have challenged the historical position of
leadership this nation has held in this important industrial sector.

These changes have resulted in a loss of current and future economic
growth in many rural U.S. regions that are dependent on the forest
products industry. And yet, within these challenging economic
conditions, tremendous new opportunities are emerging. The recently
hosted 2004 Forest Products Nanotechnology Workshop in Washington
identified nanocomposites engineered from wood biopolymers as a
unique material that could be readily utilized in several industrial
sectors.

The objective of this workshop proposal is two-fold: To develop a
broad multidisciplinary workshop directed at evaluating the research
needs, opportunities, and benefits of separating, synthesizing, and
engineering nanostructures from wood biopolymers into advanced
materials and to provide an opportunity by which national and
international experts and other interested parties in can exchange
ideas and concepts providing a unique cross- disciplinary learning
opportunity.

It is anticipated that this NSF sponsored workshop will be a pivotal
meeting that will lead to a new vision and roadmap that will
highlight the future benefits and opportunities for the development
of new nanobioterials based wood. The roadmap will leverage this
nation's position of leadership in nanotechnology with its
preeminent renewable forest resources to develop a research roadmap
that will contribute to the development of innovative value- added
nanocomposites.

The meeting will be hosted at the Institute of Paper Science and
Technology at the Georgia Institute of Technology on September 22nd
and 23rd, 2005. You may register for the meeting at
www.pe.gatech.edu/conted/servlet/edu.gatech.conted.course.ViewCourseD
et ails?COURSE_ID=732 . (Due to length of URL, please cut and paste
into browser.) For more information please contact
Art.Ragauskas@ipst.gatech.edu.

For more information contact:

David Bell, Director of Development (404) 894-9592

---------------------------------------------------------------------
-----------
Source: Institute of Paper Science

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Conference Focuses on Nanotechnology Solutions; 13th Foresight Conference

Conference Focuses on Nanotechnology Solutions; 13th Foresight
Conference Focuses on Energy, Clean Water, Health, Agriculture,
Information Technology and Development of Space

13th Foresight Conference on Advanced Nanotechnology

MENLO PARK, Calif. Sept. 1, 2005--How will nanotechnology benefit
humankind? What is currently happening in nanotech that will
translate into solutions for problems facing mankind? Panelists and
speakers will discuss nanotechnology solutions and environmental
issues surrounding the Foresight Nanotechnology Challenges at the
13th Foresight Conference: Advancing Beneficial Nanotechnology:
Focusing on the Cutting Edge, to be held October 22-27, 2005 at the
San Francisco Airport Marriott. Newcomers and veteran nanotechnology
trackers will hear how nanotechnology can help solve some of the
most critical challenges facing humankind.

The Foresight Nanotechnology Challenges are:

1. Meeting global energy needs with clean solutions
2. Providing abundant clean water globally
3. Increasing the health and longevity of human life
4. Maximizing the productivity of agriculture
5. Making powerful information technology available everywhere
6. Enabling the development of space

"There is a lot of conversation and debate about the pros, cons and
possibilities of nanotechnology," said Scott Mize, President of
Foresight Nanotech Institute. "Our conference is designed to
highlight what is happening on the cutting edge today, illuminate
how it can solve key problems facing humanity, ask the hard
questions, and contemplate the future of this powerful technology."

Panels and presentations include the following: Nanotech for Clean
Energy, Capturing the Environmental Benefits of Nanotechnology,
Assessing Risks of Nanoscale Materials, Nanotech for Clean Water,
Federal Government Regulation of Nanotechnology -- Present and
Future Trends, Health Applications of Nanotech, Nanotechnology and
the Environment, State-of-the-Art Nanotechnology for Space -- Near-
Term and Long-Term, Nanotech for Food Production and Reducing the
Environmental "Footprint" of Agriculture, Nanotech for Ubiquitous,
Inexpensive Information Technology, From Carbon Nanotubes to the
Space Elevator, and Is the Public Interest Being Protected?

Advancing Beneficial Nanotechnology: Focusing on the Cutting Edge is
organized into three stand-alone, complementary sessions -- Vision,
Applications & Policy, and Research -- featuring world-class
speakers discussing key advances, funding and applications, and
debating the controversial issues surrounding this new Industrial
Revolution.

The Vision Weekend provides a rare opportunity to hear speakers
including: Peter Diamandis, X Prize Foundation; Aubrey de Grey of
University, Cambridge; Eric Drexler, Nanorex; Carl Kohrt, Battelle;
and Richard A.L. Jones, University of Sheffield, discuss the future
of nanotechnology candidly and off-the-record. Scheduled for October
22-23, 2005, these sessions also feature a debate, "Nanotechnology:
Revolutionary or Questionable?" between Jerry Mander, Director,
International Forum an Globalization, and Ralph Merkle, Dept. of
Computer Science, Georgia Tech.

The Applications & Policy sessions focus on the Foresight
Nanotechnology Challenges, and will examine the commercial
breakthroughs and public policy actions that are driving
nanotechnology solutions to these challenges facing humanity.
Speakers include: George Atkinson, U.S. Department of State; Scott
Hubbard, NASA Ames Research Center; Randy Hayes, Rainforest Action
Network; Peter Singer, University of Toronto Joint Centre for
Bioethics; David Bishop, Lucent; Jim Von Ehr, Zyvex; and Adam
Werbach, Conservationist and former President, Sierra Club.
Scheduled for October 24-25, 2005, this segment also features
presentations and panels on nanotechnology applications for clean
energy, clean water, human health, agriculture, information
technology, and space development.

The Research sessions are a forum for researchers from all
disciplines to present and discuss important recent work and
results. The research days include technical talks from: Steve Mayo,
Caltech and Howard Hughes Medical Institute; Z.L.Wang, Georgia Tech;
Roy Bar-Ziv, Weizmann Institute of Science (Israel); William
Goddard, Caltech; Alex Zettl, UC Berkeley; and Hiroshi Yokayama,
AIST (Japan). Scheduled for October 26 and October 27, 2005, these
sessions also include a presentation on the Technology Roadmap for
Productive Nanosystems, a joint initiative between Foresight
Nanotech Institute, Battelle and The Waitt Family Foundation.

Attendees can customize this "a la carte" conference experience by
choosing the days and sessions that provide the nanotechnology
information and contacts they are seeking. Participants choosing to
attend all six days receive a comprehensive overview from Vision,
through current Applications & Policy, to Research.

Current sponsors of the Advancing Beneficial Nanotechnology
Conference are: Battelle, The Waitt Family Foundation, Biophan
Technologies, Dorsey & Whitney LLP, Zyvex, Buchanan Ingersoll,
Draper Fisher Jurvetson, Sun Microsystems, Nanoscience Technologies,
NaturalNano, Nanorex, Inc., Foley & Lardner LLP, Howard Rice
Nemerovski Canady Falk & Rabkin, White & Case, Greenberg Traurig and
nanoTITAN Incorporated.

For registration and additional details about Advancing Beneficial
Nanotechnology: please visit
http://www.foresight.org/conference2005.

About Foresight Nanotech Institute

Foresight Nanotech Institute is the leading think tank and public
interest organization focused on nanotechnology. Founded in 1986,
our mission is to ensure the beneficial implementation of
nanotechnology. Focusing on the six Foresight Nanotechnology
Challenges, Foresight provides balanced, accurate and timely
information to help society understand nanotechnology through
publications, guidelines, public policy activities, roadmaps,
prizes, tutorials, conferences, discussion forums and networking
events.

For more information about Foresight Nanotech Institute:
http://www.foresight.org.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Strand Genomics Changes Corporate Identity to Strand Life Sciences

Strand Genomics Changes Corporate Identity to Strand Life Sciences,
Launches in Silico ADMET Tool

BANGALORE, India, Sept. 1, 2005 - Strand Genomics, announced today
that it has changed its corporate identity to Strand Life Sciences,
effective immediately. It also announced the launch of its in silico
predictive ADMET tool, admetis. Strand Life Sciences website is
www.strandls.com and admetis website is www.admetis.com.

Strand has leveraged its core technologies to develop decision-
support solutions for powering drug discovery including in silico
predictive models for drug properties such as ADME and
Cardiotoxicity. In addition, Strand has an ongoing research program
in predictive modeling for hepatotoxicity. Strand partners with
discovery contract research companies in India to combine in silico
with wet lab techniques to offer consulting services starting from
compound design to lead generation.

"The change in corporate identity reflects the expanding focus of
the company. Our portfolio of products now extends beyond functional
genomics into computational chemistry.," said Vijay Chandru, CEO and
Chairman, Strand Life Sciences. "admetis addresses a key need in the
industry and can help profile compounds early."

admetis is a comprehensive tool for modeling and predicting drug-
relevant properties of molecules in silico. It gives users the power
to build custom models from scratch using their own data. This is
made possible through easy and intuitive model-building workflows
based on Strand's expertise in in silico model building. admetis
comes packaged with its pre-built models, truPK and truTox, for
predicting Bioavailability, Protein binding, Volume distribution,
Elimination half life, Rate of absorption and hERG binding. admetis
has an extensive data mining and visualization module that supports
an embedded chemical structure viewer.

"admetis couples pre-built models with a workflow-based modeling
platform making it a distinct offering." said Kas Subramanian, CSO,
Strand Life Sciences. "admetis is a highly intuitive and easy to use
tool that helps build accurate predictive models on the fly."

About Strand Life Sciences Pvt Ltd

Strand Life Sciences is a premier in silico technologies innovation
company, focused on drug discovery and development. Strand has over
the last five years, developed outstanding technologies and
capabilities in data analytics and predictive modeling in drug
discovery and development. Strand has built in-silico predictive
models for drug properties like ADME, Cardiotoxicity and has an
ongoing research program in predictive modeling for hepatotoxicity.
Strand has also developed tools for oligo design, microarray image
analysis and has executed several customer specific data analysis
projects. Strand partners with discovery contract research companies
in India to combine in silico and wet lab techniques to offer
consulting services starting from compound design to lead generation.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Increasing Adoption of Computational Biology Tools in Drug Discovery Industry

Increasing Adoption of Computational Biology Tools in Drug Discovery
Industry

LONDON, August 29, 2005 In a move aimed at augmenting shrinking
product pipelines, the drug discovery industry is employing high-
level computational biology tools. The industry also expects to
reduce the duration of the drug discovery process, especially in
toxicology and drug efficacy studies.

New analysis from Frost & Sullivan (www.biotech.frost.com), World
Computational Biology Markets, reveals that revenues in these
markets totalled USD 60.0 million in 2004 and can reach USD 751.8
million in 2011.

An increase in royalty and milestone payment agreements is
strengthening strategic partnerships between computational biology
tools vendors and drug discovery companies This, in turn, is
nurturing the faster adoption of these tools in drug discovery.

The U.S. Food and Drug Administration's (FDA) pronouncement of in-
silico biology (model-based drug development) as an important step
in improving drug development knowledge management and decision
making, has provided further support to this adoption. Besides using
it, FDA scientists are also collaborating with others in the
refinement of quantitative clinical trial modelling using simulation
software to improve trial design and predict outcomes.

The advent of HTS and ultra HTS (uHTS) has created a huge number of
drug candidates increasing the need for the drug discovery for
computational tools to investigate ADME/TOX properties at a very
early stage to arrive at decision of which of drug candidates can be
pushed into clinical trials stage.

"Use of computational biology tools eliminates false leads at the
early stages of drug discovery," says Frost & Sullivan Industry
Analyst Raghavendra Chitta. "This helps cut down costs since the
later stages are more expensive and time-consuming."

Nevertheless, adoption of these tools is still in its initial stage.
As pharmaceutical companies that have invested heavily in
computational tools after the Human Genome Project are yet to see
any tangible returns, there exists a natural scepticism about their
efficacy.

Therefore, computational biology companies have to quantify their
productivity increments through wet lab experiments to substantiate
their claims. The need of the hour for computational biology
companies is to generate success stories by working on in-house
compounds and taking them to their commercial phase.

For the increased uptake of computational biology tools it is
essential to have qualified software developers trained in biology,
chemistry, and the specific methods of modelling and simulation
needed to interpret data to improve the research process. Many
countries are setting up new academic programs tailored to meet this
specific demand.

Companies also have to be prepared to deal with the technical
inertia among biologists who consider it very difficult to implement
the complex biological system using a series of differential
equations and prefer instead to use traditional methods.

"Computational biology works by integrating data from various
sources to model a biological process," says Chitta. "Although
genomics has generated a huge deluge of information, it has also
created a new problem of varying data formats incompatible with each
other."

The increasing transfer of knowledge from the academic to commercial
sector and the drive toward data standardization through the systems
approach are likely to solve these challenges.

After the series of consolidation, which took place in the
pharmaceutical industry, these companies are looking for a single
large technological platform that can satisfy a multitude of their
research needs. Computational biology companies need to pattern
themselves to meet these requirements in order to utilize this
opportunity.

World Computational Biology Markets is part of the Drug Discovery
subscription. It evaluates pathway modelling tools, tissue modelling
tools, cellular modelling, and disease modelling tools. Analyst
interviews are available to the press.

If you are interested in an analysis, which provides manufacturers,
end users, and other industry participants with an overview,
summary, advantages and disadvantages of World Computational Biology
Markets (F351) - then send an e-mail to Katja Feick - Corporate
Communications at with the following information: your full name,
company name, title, telephone number, e-mail address, city, state
and country. We will send you the information via e-mail upon
receipt of the above information. katja.feick@frost.com

Background

Frost & Sullivan, a global growth consulting company, has been
partnering with clients to support the development of innovative
strategies for more than 40 years. The company's industry expertise
integrates growth consulting, growth partnership services and
corporate management training to identify and develop opportunities.
Frost & Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community, by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] CODA Genomics, Inc. Obtains NIAID Funding for Synthetic Biology and Protein

CODA Genomics, Inc. Obtains NIAID Funding for Synthetic Biology and
Protein Expression of DNA Mutant Gene Sets


IRVINE, Calif., Sept. 1 -- CODA Genomics, Inc.(CODA), a
synthetic biology and protein expression company, announced today
that it has
obtained NIAID funding for expansion of its synthetic gene assembly
and
protein expression technology to enable simultaneous formation of
coordinated
mutant sets of genes quickly, easily, and inexpensively. Such easy
access to
large libraries of directed mutations of natural proteins is
critical to
optimal protein-based drug discovery, rapid development of DNA
vaccines, and
exploration of protein structure/function relationships. The grant,
in excess
of $500,000, is a Small Business Technology Transfer (STTR) award
between CODA
and the University of California, Irvine (UCI). Dr. She-Pin Hung is
the
principal investigator (PI) for CODA, and Dr. Richard H. Lathrop is
the PI for
UCI.
CODA Genomics offers gene kits and services optimized to
assemble DNA into
single gene products that are guaranteed to express the desired
protein.
Current gene synthesis methods involve costly and time-consuming
PCR, DNA
sequencing, and sequence correction steps not necessary with CODA.
CODA genes
are optimized for correct self assembly, and also for
characteristics that
guarantee they express the desired protein at high levels in a
biological
expression system of choice, currently a difficult hurdle in protein
drug
discovery research. Most importantly, CODA's patented Translation
Kinetics
methods can create engineered DNA constructs that allow facile
research on
protein structure/function properties such as solubility, excretion,
and
folding.
Dr. Robert Molinari, CEO of CODA, comments, "CODA makes
synthetic biology
so robust that we can offer kits which guarantee that individual
researchers
in their own labs can assemble genes and express proteins. This
saves time
and expense. For large protein drug SAR (structure-activity
relationship)
studies, libraries of individual directed constructs can be made
easily and
quickly, with relative certainty that proteins will express
properly. We are
delighted the NIAID has chosen to fund the further development of
this
technology for large mutational studies."

CODA Genomics, Inc. was started in 2004 to commercialize the DNA
assembly
and protein expression optimization work from the laboratories of
Drs. Richard
Lathrop and G. Wesley Hatfield at the University of California,
Irvine. The
basic science was developed under a prestigious Information
Technology
Research (ITR) award to Drs. Lathrop and Hatfield from the National
Science
Foundation (NSF). In addition to DNA assembly thermodynamics, CODA
optimizes
codon usage preferences AND patented codon pair-wise combinations
that control
translational kinetics to generate high levels of the proper protein
constructs. CODA's motto, "Synthetics Genes -- Guaranteed to
Express." is put
into practice with the company's CODExpress(TM) Gene Kits and
Services. In
addition, CODA offers collaborations for protein drug and production
engineering based on large structure/activity studies of related
proteins.
These technologies allow researchers to assemble DNA constructs
reliably, more
quickly, less expensively, and on a scale never before possible.

SOURCE CODA Genomics, Inc.
Web Site: www.codagenomics.com

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Aspreva to Present at the BioCentury NewsMakers in the Biotech Industry

Aspreva to Present at the BioCentury NewsMakers in the Biotech
Industry Conference in New York

VICTORIA, BC, Sept. 2 Aspreva
Pharmaceuticals
Corporation (NASDAQ: ASPV; TSX: ASV) today announced that Noel Hall,
Aspreva's
Co-Founder and President will present at the BioCentury NewsMakers
in the
Biotech Industry Conference in New York.
The 25-minute presentation followed by a 1 hour breakout session
will
take place on Friday September 9, 2005 at 1:20 pm EDT at the
Sheraton New York
Hotel and Towers in New York.
A live audio webcast of Mr. Hall's presentation will be
available to all
interested parties through a link posted on Aspreva's website at
www.aspreva.com in the Investors section.

About Aspreva Pharmaceuticals
Aspreva is an emerging pharmaceutical company focused on
identifying,
developing and upon regulatory approval, commercializing new
indications for
approved drugs and late stage drug candidates for less common
diseases.
Aspreva's "indication partnering" strategy allows its partners to
maintain
core brand focus while extending the benefits of their medicines to
a broader
patient population. Aspreva is listed on the Nasdaq National Market
under the
trading symbol "ASPV" and on the Toronto Stock Exchange under the
trading
symbol "ASV".

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Study Reveals Genomics of Inflammation from Severe Injury

Study Reveals Genomics of Inflammation from Severe Injury
Could Improve Prediction of Patient Outcomes, Lead to Tailored
Treatments
When it comes to inflammation, too much of a good thing can be
deadly. In some severely injured patients, this normal healing
process can develop into a lethal, whole-body response, including
bloodstream infection (sepsis) and multiple organ failure. How and
why inflammation turns from healing to harming is still mysterious,
so doctors can't accurately predict how each injured patient will
fare.

To address these issues, scientists have produced the genomic
equivalent of a time-lapse movie, tracking the activity of thousands
of genes through the course of body-wide inflammation. The research
appears in the August 31 advanced online issue of Nature.

"This work represents a major step in understanding inflammation in
severely injured or burned patients. We hope this knowledge
eventually will help physicians better predict patient outcomes and
tailor treatments accordingly," said Jeremy M. Berg, Ph.D., director
of the National Institute of General Medical Sciences (NIGMS), the
component of the National Institutes of Health that funded the
research.

The study is the result of a collaborative effort funded by an
NIGMS "glue grant." Glue grants bring together scientists from
diverse fields — in this case surgery, critical care medicine,
genomics, bioinformatics, immunology and computational biology — to
solve major, complex problems in biomedical science that no single
laboratory could address on its own.

To identify all the genes involved in responding to critical injury,
the Inflammation and the Host Response to Injury glue grant team
injected healthy volunteers with bacterial endotoxin. This molecule
causes body-wide inflammation similar to sepsis, with one important
difference — it is well-defined and lasts only 24 hours. By
comparing the changes in gene activity caused by endotoxin exposure
with those caused by trauma, the researchers hope to identify the
molecular markers that spell sepsis.

The research team zeroed in on white blood cells, which help fight
infection and disease and trigger inflammation. The scientists
analyzed the activity of tens of thousands of genes from these
cells, which were taken from the volunteers at regular intervals
over 24 hours. Because this research plots the course of the
inflammatory response over time, it is particularly valuable,
according to Scott D. Somers, Ph.D., NIGMS program director of this
glue grant. "In the case of injury, time is critical. To provide the
best treatment, doctors need to know how the human body responds in
the moments and days after an injury," he said. "No other study of
injury or inflammation has tracked changes to the entire human
genome over time."

The research team found that, of the 5,000 or so genes that
fluctuated in response to endotoxin, more than half were turned
down, causing the blood cells to be less metabolically active. This
seems surprising, as one would expect genes required for healing to
be turned up and for white blood cells to be more, not less, active.
Although other research groups have seen similar genetic results in
animals, scientists don't yet have an explanation for this
counterintuitive response.

Understanding inflammation requires knowing not just which genes are
involved, but how those genes interact with each other. To
investigate this, the group turned to a knowledge base compiled by
Ingenuity Systems, Inc. of Mountain View, Calif., that includes
200,000 published reports on more than 8,000 human, rat and mouse
genes and their genetic interactions. This tool enabled the group to
uncover about 300 genes and several genetic pathways not previously
known to be involved in inflammation.

The Nature article is the second in a planned series of papers that
aim to improve understanding of the human response to injury. In its
first paper, published in March in the Proceedings of the National
Academy of Sciences, the research team described the development of
a microarray technique to analyze the entire genome of white blood
cells from healthy volunteers and critically injured patients. Next,
the team plans to study gene and protein activity in the white blood
cells of a large group of trauma and burn patients over longer
periods of time.

The glue grant team includes scientists from Stanford Genome
Technology Center in Palo Alto, Calif.; University of Medicine and
Dentistry of New Jersey-Robert Wood Johnson Medical School in New
Brunswick, N.J.; Ingenuity Systems, Inc. in Mountain View, Calif.;
University of Florida College of Medicine in Gainesville; Washington
University in St. Louis, Mo.; University of Rochester School of
Medicine in Rochester, N.Y.; and Massachusetts General Hospital,
Harvard Medical School in Boston.

To arrange an interview with Jeremy M. Berg or Scott D. Somers,
contact the NIGMS Office of Communications and Public Liaison at 301-
496-7301. For more information about the Inflammation and the Host
Response to Injury glue grant, see
http://www.nigms.nih.gov/news/releases/tompkins.html and
http://www.gluegrant.org/. For general information on glue grants,
go to http://www.nigms.nih.gov/funding/gluegrants.html.

NIGMS (http://www.nigms.nih.gov), a component of the National
Institutes of Health, supports basic biomedical research that is the
foundation for advances in disease diagnosis, treatment, and
prevention.

The National Institutes of Health (NIH) — The Nation's Medical
Research Agency — includes 27 Institutes and Centers and is a
component of the U. S. Department of Health and Human Services. It
is the primary Federal agency for conducting and supporting basic,
clinical, and translational medical research, and investigates the
causes, treatments, and cures for both common and rare diseases. For
more information about NIH and its programs, visit
http://www.nih.gov.

Biotech
Biotech
Arizona Entrepreneurs
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Milk Genomics and Human Health Symposium

Milk Genomics and Human Health Symposium

Nov. 10-11 -- International experts in nutrition, genomics,
bioinformatics and milk will gather to discuss genomic research
related to milk during the second International Symposium on Milk
Genomics and Human Health. The event, sponsored by the California
Dairy Research Foundation, will be held at COPIA: The American
Center for Wine, Food & the Arts in Napa, Calif. Speakers will
discus such topics as lactation biology, prevention of metabolic
disease, health properties of human milk, milk genomics databases
and expression tools, and updates from the International Genomics
Consortium. Among the speakers will be UC Davis faculty members J.
Bruce German and Matthew Lange, both of the Department of Food
Science and Technology, and Juan Medrano of the Department of Animal
Science.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Mass-Market Paperback Nanotechnology Primer References mPhase Technologies

Mass-Market Paperback Nanotechnology Primer References mPhase
Technologies' 'Smart' Battery; 'Nanotechnology for Dummies', latest
in light-hearted series, probes into high-growth market segment

LITTLE FALLS, N.J. Sept. 2, 2005--"Nanotechnology for Dummies," the
newest in the "Dummies" paperback series designed to simplify the
complexities of technology for average people, is a good
introduction to the topic and worth exploring by investors,
according to Ron Durando, CEO of mPhase Technologies (OTC: XDSL), a
noted pioneering company in the field.

"If you are an investor who has been confused about nanotech, here
is a good introduction that should promote your understanding of the
science, applications, and growth trajectory for nanotechnology,"
said Durando, whose company is commercializing a revolutionary nano-
based "smart" battery. He added that the company is looking into
using the smart battery in energy harvesting applications to
potentially reduce energy consumption.

The book from Wiley Publishing describes the mPhase battery in a
section called, "It just keeps on going," focusing on its ability to
store energy for decades and produce current virtually on demand.

According to Wiley Publishing, investment in nanotechnology is
exploding, with $3.7 billion in R&D spending authorized by the U.S.
government in 2003 and international investment reported at over $2
billion.

The book's author, Richard Booker, is a doctoral student at Rice
University working under Richard Smalley, discoverer of what Wiley
describes as the "buckeyball -- a collection of carbon atoms in a
spheroid shape composed of a 60 carbon atoms each bonded to three of
its neighbors." His co-author, Earl Boysen, is an experienced
engineer with degrees in physics and chemistry.

Nanotechnology is a technical discipline that uses a combination of
chemistry, physics and industrial engineering to discover and use
the special characteristics of materials at the nanometer or atomic
scale. mPhase expects multiple applications for its breakthrough
development "smart" battery.

mPhase has already proven the feasibility of fabricating such
batteries, which can store reserve power for decades and generate
electric current virtually on demand. The prototype battery is based
on a Bell Labs discovery that liquid droplets of electrolyte will
stay in a dormant state atop nanotextured surfaces until stimulated
to flow, thereby triggering a reaction producing electricity. This
effect can permit precise control and activation of the batteries
when required, yielding a very long shelf life.

About mPhase Technologies, Inc.

mPhase Technologies Inc. (OTC: XDSL) develops and commercializes
next-generation telecommunications and nanotechnology solutions,
delivering novel systems to the marketplace that advance
functionality and reduce costs. The company, awarded the 2005 Frost
& Sullivan Excellence in Technology Award, is bringing
nanotechnology out of the laboratory and into the market with a
planned innovative long life power cell. Additionally, the company
is working on prototype ultra-sensitive magnetometers that promise
up to a 1,000-fold increase in sensitivity as compared with
available uncooled sensors. More information is available at the
mPhase Web site at www.mPhaseTech.com

Safe Harbor Statement

This news release contains forward-looking statements related to
future growth and earnings opportunities. Such statements are based
upon certain assumptions and assessments made by management in light
of current conditions, expected future developments and other
factors it believes to be appropriate. Actual results may differ as
a result of factors over which the companies mentioned in this press
release have no control.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] NewsMakers in the Biotech Industry Conference to Webcast Millennium Presentation

NewsMakers in the Biotech Industry Conference to Webcast Millennium
Presentation

Millennium Pharmaceuticals, Inc. logo. (PRNewsFoto)

CAMBRIDGE, MA USA 02/07/2003

CAMBRIDGE, Mass., Sept. 2 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its
presentation at
the NewsMakers in the Biotech Industry Conference will be webcast
live and may
be accessed by visiting the Investors section of the Company's
website,
www.millennium.com.

Millennium senior management will provide an overview of the
Company and
upcoming corporate events. The presentation will be delivered at
1:20 p.m. ET
on Friday, September 9, 2005 from the Sheraton New York Hotel &
Towers in New
York City. The presentation will be archived for 30 days.

About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical
company
based in Cambridge, Mass., markets VELCADE(R) (bortzeomib)
Injection, a novel
cancer product, and has a robust clinical development pipeline of
product
candidates. The Company's research, development and commercialization
activities are focused in three therapeutic areas: oncology,
inflammation, and
cardiovascular. By applying its knowledge of the human genome, its
understanding of disease mechanisms and its industrialized drug
discovery
platform, Millennium is seeking to develop breakthrough products. The
Company's website is www.millennium.com.

Arizona Biotech
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Bay Area biotech firms release terms of IPOs ITCA SNSS
Inside Bay Area - Business News

Bay Area biotech firms release terms of IPOs

Two Bay Area biotechnology firms announced terms for initial public offerings of stock.

Emeryville-based Intarcia Therapeutics Inc., which is developing breast cancer and hepatitis C treatments, Friday announced the terms for an IPO worth as much as $70 million.

The stock is expected to list on the Nasdaq Stock Market under the symbol "ITCA."

Underwriters for Sunesis Pharmaceuticals Inc. on Thursday set the terms of the company's pending IPO at 6 million shares with an estimated price range of between $9 and $11 a share.


Sunesis company said it plans to list its common stock on the Nasdaq National Market under the symbol "SNSS."

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
New hope for green biotechnology in Germany
Checkbiotech.org

New hope for green biotechnology in Germany

Wednesday, August 31, 2005
By Catrin Bialek
Translated by Rupert Schutz, Checkbiotech

DÜSSELDORF - Green biotechnology has so far led a shadowy existence in Germany. Scientists and entrepreneurs now see their chance. The German Christian Democratic and the Liberal Parties want to change the rigid course.



Among other things, this is also because last year, the Second Genetic Engineering Act further tightened the conditions for cultivation of genetically modified plants.

“Under laboratory conditions one can do almost everything here, but to move to outdoor tests isn’t feasible at the moment,” states Ricardo Gent, managing director of the German Association of Biotechnology Industries.


Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Creamer Media's Engineering News Online, South African Industry News :: Breaking News
Creamer Media's Engineering News Online, South African Industry News :: Breaking News


Expo celebrates commercial biotechnology
--------------------------------------------------------------------------------

South Africa's first Biotechnology Expo - Biotech Africa - that runs at the Sandton Convention Centre from October 18 to October 20 is timed to coincide with the 10th year of commercial use of plant biotechnology products around the world.

This milestone also marks more than 20 years of research and development in agricultural biotechnology. While many people are still under the impression that biotechnology is a new, untested science, the first seeds actually went into the ground in 1996 and, since then, biotech crops have been planted and grown on a total area of 385-million hectares - an area roughly equivalent to 40% of the entire US or China and 15 times the total land area of the UK - by more than 10-million farmers in 20 countries worldwide.

The establishment of Biotech Africa, the first local Biotech expo, marks another step in the development of the plant biotechnology industry in South Africa.

This is not, however, to say that Biotech Africa will be focused on plant biotechnology - the exhibition covers the full spectrum of biotechnology including plant, industrial, environmental, human health, pharmaceutical and bioinformatics.


Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Anadys Pharmaceuticals to Present at BioCentury's 12th Anniversary Newsmakers in the Biotech Industry Conference
Anadys Pharmaceuticals to Present at BioCentury's 12th Anniversary Newsmakers in the Biotech Industry Conference


SAN DIEGO, Sept. 2 -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) announced today that it will be presenting at BioCentury's 12th
Anniversary NewsMakers in the Biotech Industry Conference on Friday, September
9, 2005, at 1:20 p.m. Eastern Time in the Liberty 3 suite at the Sheraton New
York Hotel & Towers, 811 Seventh Avenue, New York City. The presentation will
be simultaneously webcast and can be accessed on the Company's website at
http://www.anadyspharma.com.
Kleanthis G. Xanthopoulos, Ph.D., Anadys' President and Chief Executive
Officer, will present an overview of Anadys and its clinical development and
discovery programs.
Listeners are encouraged to visit the website approximately 5 minutes
prior to Anadys' presentation to download or install any necessary software. A
replay of the presentation will become available approximately one hour after
the live webcast concludes and will be archived and available until September
23, 2005.

About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to
advancing patient care by discovering, developing and commercializing novel
small molecule medicines for the treatment of hepatitis C virus (HCV),
hepatitis B virus (HBV) and other serious infections. The Company has core
expertise in Toll-Like Receptor-based small molecule therapeutics and
structure-based drug design coupled with medicinal chemistry. Anadys'
clinical development programs include ANA975 for the treatment of HCV and HBV,
and ANA380 for the treatment of HBV. In addition, Anadys' therapeutic platform
is designed to advance a strong and continual pipeline of drug candidates into
the clinic.

Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause Anadys' actual results to be materially different from
historical results or from any results expressed or implied by such forward-
looking statements. In particular, the results of initial clinical trials may
not be predictive of future results, and Anadys cannot provide any assurances
that any of its product candidates will have favorable results in future
clinical trials or receive regulatory approval. In addition, Anadys' results
may be affected by risks related to the implementation of its collaboration
with Novartis, competition from other biotechnology and pharmaceutical
companies, its effectiveness at managing its financial resources, its ability
to successfully develop and market products, the level of efforts that its
collaborative partners devote to development and commercialization of its
product candidates, difficulties or delays in its clinical trials,
difficulties or delays in manufacturing its clinical trials materials, the
scope and validity of patent protection for its products, regulatory
developments involving future products and its ability to obtain additional
funding to support its operations. These and other factors that may cause
actual results to differ are more fully discussed in the "Risk Factors"
section of Anadys' Form 10-Q for the quarter ended June 30, 2005. All forward-
looking statements are qualified in their entirety by this cautionary
statement. Anadys is providing this information as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or otherwise.



SOURCE Anadys Pharmaceuticals, Inc.
Web Site: http://www.anadyspharma.com

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Holmes Herbs Creates Holmes Biopharma Division

Holmes Herbs Creates Holmes Biopharma Division

SCOTTSDALE, Arizona Aug. 24, 2005--Holmes Herbs, Inc., (OTCBB:HMHB),
announced today that it has created a division called Holmes
Biopharma, for the purpose of entering into the clinical drug
research and drug development business.

The company has launched a new website for investors and clients at
www.holmesherbs.com and www.holmesbiopharma.com.

"Our strategy is to create one new drug research facility and
acquire another existing facility in the coming months" stated John
Metcalfe, President and CEO.

On behalf of the Board of Directors

John F. Metcalfe, President and CEO

Certain statements in this press release constitute "forward looking
statements" within the meaning of the United States Securities
Legislation. The Company's actual results could differ from those in
the forward-looking statements. Do not construe this information as
investment advice. This is not a solicitation to buy or sell
securities. This does not purport to be a complete analysis of the
Company. Investing in securities is speculative and carries a high
degree of risk. Past performance does not guarantee future results.
Readers should consult their own independent advisers with any
investment, including any contemplated investment. All information
contained in this press release should be independently
investigated. This press release contains forward-looking
statements. These remarks involve risks and uncertainties. Risks are
not limited to quarterly fluctuations in results or the companies'
management of growth and competition. Other risks are detailed in
the Company's SEC filings. Actual results may differ materially from
such information set forth herein.

Holmes Herbs, Inc. (OTC Bulletin Board:HMHB)

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Biotech Pauses for Breath in August

Biotech Pauses for Breath in August


SAN FRANCISCO, Sept. 1 -- August is typically a slow month as
far as the capital markets are concerned and this year was no
exception. "This was certainly the case for biotech as the momentum
that industry has enjoyed
over the past four months tailed off," said G. Steven Burrill, CEO
of Burrill
& Company, a San Francisco based global leader in life sciences whose
principal activities are in Venture Capital, Merchant Banking and
Media.
"After biotech's strong run over the past four months, it was not
unexpected that there would be a cooling off period. However,
biotech has not
been caught in the downdraft affecting other markets but has remained
relatively stable during the past four weeks ... and has even shown
some
strength over the general market.
"With oil prices soaring, the price of a gallon of gas hitting
$3 at the
pump already, and consumer confidence weakening, the Burrill Biotech
Select
Index still managed to break even in August beating the Dow Jones
Industrial
Average, which closed down 1.5% and the NASDAQ, which was also off
by the same
amount," added Burrill.

Biotech Market Cap Race
Thanks to a last day of the month surge in its share price, and
Amgen's
shares remaining unchanged for the month, Genentech once again
captured top
ranking as the biotech company with the highest market cap. Closing
at $93.94,
Genentech's market cap stood at $99.97 billion, just above that of
Amgen,
whose market cap was $98.58 billion.
"It is interesting to note in this market cap rivalry that the
combined
market caps of Genentech and Amgen represents 41% of the collective
total of
the biotech industry, which at the end of August, stood at $474.13
billion,"
commented Burrill.
Genentech's share price was boosted on the news that they and
Biogen Idec,
Inc. (BIIB) had submitted a supplemental Biologics License
Application (sBLA)
with the FDA for a new indication for Rituxan (Rituximab) in
patients with
active rheumatoid arthritis (RA) who inadequately respond to an anti-
TNF
therapy.
The swing towards mergers and acquisitions with the absence of a
vibrant
IPO window continues. Dominating the headlines in August was OSI
Pharmaceutical's (OSIP) acquisition of Eyetech Pharmaceuticals
(EYET) for $935
million, representing about $20 per share, a 43% premium over
Eyetech's most
recent pre-merger announcement closing share price of $14.
"Even though the reaction from the Street to this deal was
decidedly mixed,
it is unlikely that we have seen the end of high profile M&A's,"
added Burrill.
"With big pharma on the prowl for promising drug candidates to
bolster their
product pipelines and with many companies still trading at
relatively low
valuations despite the rebound in the biotech indices in the second
quarter,
there are plenty of deals yet to be made.
"Nevertheless, we are continuing to see very strong performances
from some
of the companies in the Burrill Biotech 2003/4/5 IPO Index including
New River
Pharmaceuticals (NRPH), which, since it went public a year ago, has
risen over
400%. It is these types of gains and the general improvement of the
recent IPO
'class' that will be the forerunner for an early fall opening of the
IPO
window," Burrill stated.
"In addition, the recent success of the initial public offering
of Coley
Pharmaceutical Group Inc. (COLY) earlier in August, which priced six
million
shares at $16 per share at the top its estimated pricing range
should add
further confidence for other companies waiting on the IPO runway."
The
underwriters of the offering exercised in full their over-allotment
option to
purchase an additional 900,000 shares of common stock at the public
offering
price of $16.00 per share. With the purchase of the over-allotment
shares, and
a simultaneous private placement to Coley's collaboration partner,
Pfizer
Inc., a total of 7,525,000 shares of common stock were sold,
resulting in
gross proceeds of $120.4 million.
Coley's TLR Therapeutics(TM) act by stimulating toll-like
receptors
(TLRs), found in and on immune system cells, which, in turn, direct
the immune
system to fight disease. Coley focuses on drugs for cancers,
infectious
diseases and respiratory disorders. The company has signed lucrative
deals
with big- pharma such as Pfizer (PFE) and Sanofi-Aventis (SNY).
Shortly after
their IPO shares reached $18.45, before dropping back to close out
the month
at $16.25, an increase of 1.5% from the offering price.

Burrill Biotech 2003/4/5 IPO Index (Up 2.7%, down 6.9% YTD)
The appetite for IPOs, which has been virtually non-existent for
almost
four months, could return if this IPO class maintains their
collective steady
improvement. In August, thanks to spectacular gains by Myogen
(MYOG), which
rose a remarkable 89%, to close at $20.70, the Burrill Biotech
2003/4/5 IPO
Index posted a modest gain of 2.7% Although Myogen was trading in
the $6 range
four months ago, its dramatic increase was fuelled by the news that
Myogen's
Phase IIb clinical data for its drug darusentan had shown to be
effective in
treating patients with hypertension who have not responded well to
standard
drug regimens. The company now plans to proceed with Phase III
clinical trials
for the drug. Myogen currently has one drug on the market, in
Europe, called
Perfan, a treatment for heart failure. In addition to darusentan,
the company
is developing a treatment for pulmonary hypertension called
ambrisentan
New River Pharmaceuticals (NRPH) once again posted an impressive
25% gain,
closing at $43.09, on news that the company would emphasize its
abuse-
deterring formulation of hydrocodone, rather than its abuse-deterring
formulation of hydromorphone. The company says that it also remains
on track
to file this fall for FDA approval of its formulation of amphetamine
for ADHD.
Also chipping in with solid gains was Eyetech (EYET) following
the
announcement that OSI Pharmaceuticals planned to acquire the
company. Eyetech
closed up a respectable 61% at $18.28. MannKind Corporation (MNKD)
also closed
up 54% for the month. The company completed a $175 million private
placement
of newly issued shares of common stock and the concurrent issuance
of warrants
for the purchase of additional shares of common stock.
Not so fortunate was Renovis (RNVS) who announced disappointing
results
from its Phase II clinical trial studying REN-1654 in patient-
volunteers with
sciatica, a form of neuropathic pain. The results indicate that,
although REN-
1654 showed a positive trend in pain relief, it did not reach
statistical
significance in its primary endpoint of change in average daily
spontaneous
pain ratings at the end of a three-week treatment period compared to
placebo.
Its shares closed at $13.26, down 13% on the month.

Burrill Biotech Select Index (Up 0.38% and 15.8% YTD)
For once, it wasn't Genentech (DNA) or Amgen (AMGN) keeping the
Burrill
Biotech Select Index in positive territory, with Amgen closing out
the month
unchanged and Genentech posting a late 5% surge. It was Vertex
Pharmaceuticals
Inc. (VRTX) that carried the load in August closing up 15% at
$18.05. The gain
was spurred by analysts at J.P. Morgan who upped their rating of the
biotechnology stock to overweight from neutral. They based their
upgrade on
promising Phase I clinical data on the company's hepatitis C virus
(HCV)
treatment, VX-950 for which the company expects to be able to file
for U.S.
regulatory approval in 2008.
CuraGen Corp.'s (CRGN) shares slipped and closed the month at
$4.37, down
31%. News that it expects to generate about $21 million in a public
offering
of its stock to pay down debt was not well received by its
shareholders. Its
stock is down about 34% year to date.

Burrill LARGE-CAP Biotech Index (up 0.9%, 21.4% YTD)
Shares of Genzyme Corp. (GENZ) were off 4% for the month largely
due to a
downgrade by Lehman Brothers, who cited risks to long-term growth
for a number
of the biotechnology company's products. Also dragging the Index
into negative
territory was Human Genome Sciences Inc. (HGSI), whose shares closed
at
$12.91, down 12% for August. The news that GlaxoSmithKline (NGSK) had
exercised its option to develop and commercialize HGS-ETR1
(mapatumumab)
jointly with Human Genome Sciences obviously failed to impress
investors.

Burrill MID-CAP Biotech Index (-4.9%, 3.2% YTD)
DOV Pharmaceutical Inc.'s (DOVP) 29% drop in its share price
helped
contribute to the 5% loss that the Burrill MID-CAP Biotech Index
sustained in
August. DOV Pharmaceutical suspended further dosing in a pivotal-
stage
clinical trial of ocinaplon, its experimental anti-anxiety agent,
due to
concerns about liver enzyme levels. The company said it will
continue to
monitor the subjects and patients currently enrolled in the trial.
Once the
analysis is complete, it will decide whether to continue with
ocinaplon or
select a back-up compound.

Burrill SMALL-CAP Biotech Index (-0.8%, - 10.7% YTD)
Although almost 70% of the companies in the Burrill SMALL-CAP
Biotech
Index lost ground in August, the Index only recorded a 0.8% drop.
The negative
numbers were offset in part by NeoRx Corporation (NERX), which was
the biggest
gainer closing the month at $1.01, up 53%. The company reported a
positive
second quarter initiating a Phase II clinical trial in patients with
small
cell lung cancer. NeoRx also joined with The Scripps Research
Institute in the
first scientific collaboration at Scripps Florida, focusing on
developing
therapeutic agents to treat cancer. The company believes that this
collaboration potentially will offer important opportunities to
license novel
cancer products for its pipeline.
Although both Aphton Corp. (APHT) and Avancis Pharmaceutical
Corp. (AVNC)
did not issue any significant news during the month, their stock
price dipped
by 28% and 37% respectively. In addition, following a decline in
its share
price Kosan Biosciences Incorporated (KOSN) terminated a planned
offering of
4,500,000 shares of common stock. The company's share price closed
the month
at $7.35, down 18%.

Percent
Percent
Index 12/31/04 7/29/05 8/31/05 Change
Change
Value Value Value For Month
For Year

Burrill Biotech
Select Index 287.54 331.71 332.98 0.38%
15.80%
Burrill LARGE-CAP
Biotech Index 368.59 443.34 447.49 0.94%
21.41%
Burrill MID-CAP
Biotech Index 162.53 176.54 167.79 -4.96%
3.24%
Burrill SMALL-CAP
Biotech Index 148.96 134.14 132.96 -0.88% -
10.74%
Burrill Genomics
Index 135.16 141.63 137.13 -3.17%
1.46%
Burrill Biotech
2003/4/5 IPO Index 78.11 70.80 72.70 2.68% -
6.93%
Burrill Agbio
Index 111.02 113.57 109.72 -3.38% -
1.17%
Burrill Industrial
Biotech Index 124.23 133.48 130.35 -2.35%
4.92%
Burrill Diagnostics
Index 105.30 104.15 103.95 -0.19% -
1.28%
Burrill
Nutraceuticals
Index 333.89 420.79 436.01 3.62%
30.58%
Burrill Life
Science Composite
Index 200.25 224.53 227.35 1.26%
13.54%

Percent
Percent
Index 12/31/04 7/29/05 8/31/05 Change
Change
Value Value Value For Month
For Year
Burrill Biotech
Select Index 287.54 331.71 332.98 0.38%
15.80%
NASDAQ 2175.44 2184.83 2152.09 -1.50% -
1.07%
DJIA 10783.01 10640.91 10481.60 -1.50% -
2.80%
Russell 2000 651.57 679.75 666.51 -1.95%
2.29%

SOURCE Burrill & Company

Biotech
Biotech
Arizona High Tech
Biotech News
Biotechnology
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Arizona Weblogs Directory - Hurricane Katrina Disaster Response
Arizona Weblogs Directory - Hurricane Katrina Disaster Response

We encourage you to help in the response to the disaster of Hurricane Katrina. If you have not yet donated to help the victims of Hurricane Katrina, please visit the "American Red Cross - Preparing for and Responding to Hurricane Katrina" site below.
American Red Cross - Preparing for and Responding to Hurricane Katrina

This message is posted on all of the following weblogs which are members of the Arizona Weblog Directory

Recipes
Famous Recipes
Funny Jokes
Daily Bible Verse
Famous Quotes
Life Story Writing
World Famous Recipes
Christmas
Search Engines
Love Poems
Famous Quotes
Arizona News
Funny Quotes
Famous Quotes
Cooking Recipe
Jobs and Employment
Wireless LAN
WLAN
Writing Resources
Arts and Entertainment
Quotes Exchange
Online Jewelry Stores
Jewelry Stores
Post Secrets
E-Commerce Solutions
Personal Finance
Stock Quotes
Famous People
Payday Loans
Arizona Weblog
Books and Book Reviews
Phoenix Arizona
Arizona Biotech
Chicken Recipes
Arizona News
Gatlinburg Cabins
Phoenix Arizona
480 Area Code Guide
Bible Study Online
Progressive Arizona Network
SR22
Scottsdale Dentist
Phoenix Arizona Relocation
Health Wellness Fitness
Katheesuegee
Daisy Dear
Stock Market
Free Recipes Online
Funny Jokes
Diabetic Recipes
Garden Center
sms.ac
Free Recipes
Search Engine Optimization

================================

Arizona Weblog Directory
Arizona Weblogs Directory
Recipes
Arizona Weblog Directory
Arizona Weblog Directory
Arizona Weblog Directory
Arizona Weblog Directory
Help Make Blogs More Visible!
Help Make Blogs More Visible! Latest Code
Help Make Blogs More Visible! - World Famous Recipes
Hurricane Katrina Disaster Response - World Famous Recipes
East Valley Living

Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Hurricane Katrina Disaster Response
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech